interferon gamma-1b

REMS

Diminished severity and frequency of infectious complications of chronic granulomatous disease.
Slow disease progression in severe, malignant osteopetrosis.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Hypersensitivity to interferon gamma, Escherichia coli–derived products, mannitol, or polysorbate.

Use Cautiously in:

cardiovascular disease;
Bone marrow depression;
Pregnancy, lactation, or children <1 yr (safety not established).

Adv. Reactions/Side Effects ⬆ ⬇

Derm: rash

GI: nausea, vomiting, abdominal pain

Hemat: neutropenia, thrombocytopenia

Local: edema or tenderness at injection site

MS: arthralgia, myalgia, back pain

Neuro: headache, decreased mental status, dizziness, gait disturbances

Misc: chills, fever

Interactions ⬆ ⬇

Drug-drug:

May have additive bone marrow–depressing effects with antineoplastics or radiation therapy.

Availability ⬆ ⬇

Injection: 100 mcg (3 million units)/vial

Route/Dosage ⬆ ⬇

Body Surface Area >0.5 m2

SC (Children ): 50 mcg/m² (1 million units/m²) 3 times weekly.

Body Surface Area 0.5 m2

SC (Children >1 yr): 1.5 mcg/kg 3 times weekly.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

A protein produced by recombinant DNA technology that is capable of activating phagocytes, enhancing their ability to kill pathogens, including:
- Staphylococcus aureus,
- Toxoplasma gondii,
- Leishmania donovani,
- Listeria monocytogenes,
- Mycobacterium avium intracellulare.
Interferon gamma has antiproliferative effects superior to interferon alpha and beta.

Therapeutic effects:

Decreased incidence and severity of infection in patients with chronic granulomatous disease.
Slowed disease progression of severe, malignant osteopetrosis.

Classifications ⬆ ⬇

Therapeutic Classification: immune modifiers

Pharmacologic Classification: interferons

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed after SUBQ administration.

Distribution: Unknown.

Metabolism/Excretion: Unknown.

Half-Life: 5.9 hr.

Time/Action Profile ⬆ ⬇

(blood levels)

ROUTE	ONSET	PEAK	DURATION
SUBQ	unknown	4 hr	unknown

Patient/Family Teaching ⬆ ⬇

Home Care Issues: Instruct patient or family on proper technique for administering injection and care and disposal of equipment. Provide a puncture-proof container for disposal of needles.
- Advise patient of the need for contraception throughout therapy.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

17089- Guna spa
- 17089-378- GUNA-INF GAMMA
  - 17089-378-18- 1 BOTTLE, DROPPER in 1 BOX (17089-378-18) / 30 mL in 1 BOTTLE, DROPPER

75987- Horizon Therapeutics USA, Inc.
- 75987-111- ACTIMMUNE
  - 75987-111-11- 12 VIAL, SINGLE-DOSE in 1 CARTON (75987-111-11) / .5 mL in 1 VIAL, SINGLE-DOSE (75987-111-10)

section name header

Indications ⬇